医療機関の薬剤部門における使用成績調査業務への関与に関するアンケート調査

抄録

Guidance on Risk Management Plan (RMP) for pharmaceuticals was announced in April 2012 in Japan. RMPs include post-marketing pharmacovigilance and risk minimization activities.
Treatment outcome studies have been the main part of post-marketing surveillance (PMS) in Japan, which are carried out based on a contract between a company and a medical institution.
However, there has been no report exploring the relation between pharmacies in medical institutions and treatment outcome studies in general. Therefore, we carried out a questionnaire survey in medical institutions in Tokyo to obtain information on their implementation systems of treatment outcome studies. As a result, pharmacies in 77 of 166 medical institutions are somehow engaged in treatment outcome studies, but most of their duties involve business such as the inquiry counter or the contract. It was also shown that there is little incentive for pharmacies to support treatment outcome studies.